2023
2022
2021
2020
2022-12-11
All-China Federation of Industry & Commerce, Medical& Pharmaceutical Chamber released the “2021 List of Most Influential Corporations in the Chinese Pharmaceutical Industry” online recently. Hanhui Pharma was awarded two honors “2021 Top 50 Fast-growing Chinese Pharmaceutical Enterprises” and “2021 Legal Compliance and Integrity Enterprise in the Chinese Pharmaceutical Industry”; meanwhile, the parent company Hisun Pharmaceuticals won the title of “Top 100 Pharmaceutical Enterprises of China”.
2022-08-03
During the 14th Annual Health China Forum sponsored by People's Daily Health and Health Times released the List of Top Ten New Drugs (in China) on August 3, 2022, Saisimei® (Hybutimibe) awarded the honor. Saisimei® is the only Class I innovative cardiovascular drugs approved in China in recent years, as well as the first cholesterol absorption inhibitor with independent intellectual property rights in China for the treatment of primary hypercholesterolemia.
2022-03-09
Improving the comprehensive average land benefit is important to promote the high-quality development of the manufacturing industry. In front of the increasingly prominent land restriction factors, Hanhui Pharma focuses on high-quality development, competitiveness improvement and modernization, continues to optimize the allocation of resources and elements to precisely facilitate industrial upgrading and technological innovation. Hanhui ranks among the top 10 bio-pharmaceutical enterprises in Zhejiang Province in terms of Comprehensive Average Land Benefit. It is the only bio-pharmaceutical enterprise selected in Fuyang District.
2022-01-24
The first commercial batch of Tazocin® was manufactured by the process steps of charging, on-line weighing, quantitative filling of the sterile solution, automatic delivery of the sterile product to the lyophilizer, and freezing, sublimation, and drying of the sterile solution on January 24, 2022. This is the first time that Hanhui Pharma has realized the localization of injection products, marking a new member of the company's localized products!
2022-12-11
All-China Federation of Industry & Commerce, Medical& Pharmaceutical Chamber released the “2021 List of Most Influential Corporations in the Chinese Pharmaceutical Industry” online recently. Hanhui Pharma was awarded two honors “2021 Top 50 Fast-growing Chinese Pharmaceutical Enterprises” and “2021 Legal Compliance and Integrity Enterprise in the Chinese Pharmaceutical Industry”; meanwhile, the parent company Hisun Pharmaceuticals won the title of “Top 100 Pharmaceutical Enterprises of China”.
2022-08-03
During the 14th Annual Health China Forum sponsored by People's Daily Health and Health Times released the List of Top Ten New Drugs (in China) on August 3, 2022, Saisimei® (Hybutimibe) awarded the honor. Saisimei® is the only Class I innovative cardiovascular drugs approved in China in recent years, as well as the first cholesterol absorption inhibitor with independent intellectual property rights in China for the treatment of primary hypercholesterolemia.
2022-03-09
Improving the comprehensive average land benefit is important to promote the high-quality development of the manufacturing industry. In front of the increasingly prominent land restriction factors, Hanhui Pharma focuses on high-quality development, competitiveness improvement and modernization, continues to optimize the allocation of resources and elements to precisely facilitate industrial upgrading and technological innovation. Hanhui ranks among the top 10 bio-pharmaceutical enterprises in Zhejiang Province in terms of Comprehensive Average Land Benefit. It is the only bio-pharmaceutical enterprise selected in Fuyang District.
2022-01-24
The first commercial batch of Tazocin® was manufactured by the process steps of charging, on-line weighing, quantitative filling of the sterile solution, automatic delivery of the sterile product to the lyophilizer, and freezing, sublimation, and drying of the sterile solution on January 24, 2022. This is the first time that Hanhui Pharma has realized the localization of injection products, marking a new member of the company's localized products!
2022-01-20
Hanhui Pharma obtained the drug clinical trial approval of HS301 tablets (40 mg and 80 mg) issued by NMPA on January 20, 2022, which means that HS301 tablets is approved to conduct clinical trials in locally advanced or metastatic solid tumors for this product, a milestone in the life circle of Hanhui innovative drug application.
2021-12-16
On December 16, 2021, Zai Lab, an innovative global bio-pharmaceutical company, announced that its product, Nuzyra® (Omadacycline Tosilate), has been approved by NMPA as Category I new drug for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infection (ABSSSI). Hanhui Pharma has been granted exclusive promotion rights for Nuzyra® in mainland China.
2021-12-08
The Pharmaceutical Industry-Education Integration Base of Bijie Medical College & Hanhui Pharmaceutical Co., Ltd. was established on December 8. The project with first phase of three years will efficiently speed up the construction and operation of the integration system of internship and employment between the college and Hanhui. It explores and implements the pilot program of modern apprenticeship system, by which the students will receive education from both college and enterprise. This project will provide talents for the pharmaceutical industry, promote the co-education and sharing of talents between colleges and enterprises to achieve a high degree of fit between talent training, industry needs and job positions.
2021-12-03
On December 3, 2021, the National Healthcare Security Administration published the 2021 National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance. Saisimei® (Hybutimibe Tablets), the first cholesterol absorption inhibitor with independent intellectual property rights in China, has been included in the NRDL. It is indicated as adjunctive therapy to diet, either alone or with HMG-CoA reductase inhibitors (statins), for the treatment of primary (heterozygous familial or non-familial) hypercholesterolemia, reducing total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), Apolipoprotein B (ApoB) levels.
2021-11-23
On November 23, 2021, the supplementary application of Hanhui Pharma for Piperacillin Sodium and Tazobactam Sodium for Injection (Tazocin®) was approved by NMPA, i.e., NMPA approved Pfizer Limited to transfer the manufacturing technology of its innovator product Piperacillin Sodium and Tazobactam Sodium for Injection to Hanhui Pharma.
2021-12-16
On December 16, 2021, Zai Lab, an innovative global bio-pharmaceutical company, announced that its product, Nuzyra® (Omadacycline Tosilate), has been approved by NMPA as Category I new drug for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infection (ABSSSI). Hanhui Pharma has been granted exclusive promotion rights for Nuzyra® in mainland China.
2021-12-08
The Pharmaceutical Industry-Education Integration Base of Bijie Medical College & Hanhui Pharmaceutical Co., Ltd. was established on December 8. The project with first phase of three years will efficiently speed up the construction and operation of the integration system of internship and employment between the college and Hanhui. It explores and implements the pilot program of modern apprenticeship system, by which the students will receive education from both college and enterprise. This project will provide talents for the pharmaceutical industry, promote the co-education and sharing of talents between colleges and enterprises to achieve a high degree of fit between talent training, industry needs and job positions.
2021-12-03
On December 3, 2021, the National Healthcare Security Administration published the 2021 National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance. Saisimei® (Hybutimibe Tablets), the first cholesterol absorption inhibitor with independent intellectual property rights in China, has been included in the NRDL. It is indicated as adjunctive therapy to diet, either alone or with HMG-CoA reductase inhibitors (statins), for the treatment of primary (heterozygous familial or non-familial) hypercholesterolemia, reducing total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), Apolipoprotein B (ApoB) levels.
2021-11-23
On November 23, 2021, the supplementary application of Hanhui Pharma for Piperacillin Sodium and Tazobactam Sodium for Injection (Tazocin®) was approved by NMPA, i.e., NMPA approved Pfizer Limited to transfer the manufacturing technology of its innovator product Piperacillin Sodium and Tazobactam Sodium for Injection to Hanhui Pharma.
2021-11-06
During the 4th China International Import Expo, Hanhui Pharma signed a strategic cooperation agreement with the Yilijk Internet medical platform on November 6. The two parties will integrate resources and jointly explore the digital full-course management model for chronic diseases such as digestion and hyperlipidemia, and create a high-quality closed loop of out-of-hospital health management for patients with chronic diseases.
2020-12-15
A signing ceremony was successfully held in Shanghai between Hanhui Pharma and GloriousMed for the exclusive commercial distributorship of the breast cancer precision diagnosis and treatment products in mainland China. Hanhui Pharma will provide marketing and sales services for GloriousMed to jointly promote the rapid development of the integration of breast cancer precision diagnosis and treatment.
2020-09-25
The People's Government of Zhejiang Province announced the list of “2019 Zhejiang Governmental Quality Award”. Hanhui Pharma become the only award-winning enterprise in the category of "Life and Health Industry”. It is reported that the "Zhejiang Governmental Quality Award" is the highest quality award in Zhejiang Province established by the People's Government of Zhejiang Province. It is a reward for organizations that engaged in product production, engineering construction, service provision, and environmental protection, and have implemented excellent performance management and achieved significant economic and social benefits. The award has been held for seven times. So far, Hanhui Pharma is the second pharmaceutical enterprise to win the honor.
2020-07-01
Hanhui Pharma announced it has entered into a strategic cooperation with WeDoctor Group (Zhejiang) Co., Ltd. The parties will jointly focus on chronic disease prevention, treatment and management, promote digital medical innovation and benefit more doctors and patients.
2020-03-20
Hanhui Pharma announced it has entered into a strategic cooperation agreement with Zai Lab to obtain the exclusive rights to promote Omadacycline Tosilate in mainland China. The collaboration, based on rich experience of Hanhui Pharma in promoting anti-infective products and leading pharmaceutical research and development capabilities of Zai Lab, will accelerate patients' access to Omadacycline Tosilate, the world's leading innovative anti-infective drug, thereby contributing to improving national health, extending human life span and improving quality of life.
2020-12-15
A signing ceremony was successfully held in Shanghai between Hanhui Pharma and GloriousMed for the exclusive commercial distributorship of the breast cancer precision diagnosis and treatment products in mainland China. Hanhui Pharma will provide marketing and sales services for GloriousMed to jointly promote the rapid development of the integration of breast cancer precision diagnosis and treatment.
2020-09-25
The People's Government of Zhejiang Province announced the list of “2019 Zhejiang Governmental Quality Award”. Hanhui Pharma become the only award-winning enterprise in the category of "Life and Health Industry”. It is reported that the "Zhejiang Governmental Quality Award" is the highest quality award in Zhejiang Province established by the People's Government of Zhejiang Province. It is a reward for organizations that engaged in product production, engineering construction, service provision, and environmental protection, and have implemented excellent performance management and achieved significant economic and social benefits. The award has been held for seven times. So far, Hanhui Pharma is the second pharmaceutical enterprise to win the honor.
2020-07-01
Hanhui Pharma announced it has entered into a strategic cooperation with WeDoctor Group (Zhejiang) Co., Ltd. The parties will jointly focus on chronic disease prevention, treatment and management, promote digital medical innovation and benefit more doctors and patients.
2020-03-20
Hanhui Pharma announced it has entered into a strategic cooperation agreement with Zai Lab to obtain the exclusive rights to promote Omadacycline Tosilate in mainland China. The collaboration, based on rich experience of Hanhui Pharma in promoting anti-infective products and leading pharmaceutical research and development capabilities of Zai Lab, will accelerate patients' access to Omadacycline Tosilate, the world's leading innovative anti-infective drug, thereby contributing to improving national health, extending human life span and improving quality of life.
2020-01-23
On January 23, Hisun Pharma and Hanhui Pharma donated 5,000 Solu-Medrol (Methylprednisolone Sodium Succinate for Injection 40 mg), 500 Junte (Imipenem and Cilastatin Sodium for Injection 1.0 g) and 100 Lixing (Tigecycline for Injection) for Wuhan Pulmonary Hospital, which could benefit 400 patients.
